
National Atomic Company Kazatomprom JSC
Notes to the Consolidated Financial Statements – 31 December 2025
33
23 Investments in Joint Ventures (Continued)
Summarised financial information on respect of the Group’s material joint ventures is set out below. The summarised financial information below represents amounts shown in the
joint ventures’ financial statements prepared in accordance with IFRS accounting standards, adjusted by the Group for equity accounting purposes.
Semizbay-U LLP Ulba-FA LLP SKZ-U LLP Other Total In millions of Kazakhstani Tenge 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 Current assets 67,223 75,899 369,886 377,609 3,361 3,870 3,843 3,456 444,313 460,834 Including cash 29,882 5,034 1,039 52,683 381 1,003 993 840 32,295 59,560 Non-current assets 39,488 34,155 54,456 19,814 23,533 20,414 77,129 4,952 194,606 79,335 Total assets 106,711 110,054 424,342 397,423 26,894 24,284 80,972 8,408 638,919 540,169 Current liabilities (15,703) (16,301) (363,081) (387,063) (2,176) (1,202) (2,580) (2,499) (383,540) (407,065) Including financial liabilities net of trade and other accounts payable and provisions (8,193) (7,952) (11,686) (12,616) - - - - (19,879) (20,568) Non-current liabilities (7,645) (7,316) (52,483) (13,410) (2,658) (2,728) (45,067) (39) (107,853) (23,493) Including financial liabilities net of trade and other accounts payable and provisions - (66) - (11,654) - - - - - (11,720) Total liabilities (23,348) (23,617) (415,564) (400,473) (4,834) (3,930) (47,647) (2,538) (491,393) (430,558) Net assets 83,363 86,437 8,778 (3,050) 22,060 20,354 33,325 5,870 147,526 109,611 Group’s share of net assets of joint ventures 42,515 44,083 4,478 (1,556) 10,810 9,974 15,214 4,269 73,017 56,770 Goodwill 4,105 4,105 - - 90 90 (1,464) (1,464) 2,731 2,731 Share in accumulated unrecognised losses - - - 1,556 - - - - - 1,556 Impairment losses - - - - - - (21) (21) (21) (21) Other 132 132 - - (132) - 1,562 994 1,562 1,126 Unrealised profit (3,442) (8,557) - - - - - - (3,442) (8,557) Carrying value of investments in joint ventures 43,310 39,763 4,478 - 10,768 10,064 15,291 3,778 73,847 53,605 Total revenue 81,114 95,508 272,958 163,593 17,332 15,762 5,151 4,371 376,555 279,234 Depreciation and amortisation (9,544) (7,869) (1,053) (984) (1,455) (1,341) (510) (403) (12,562) (10,597) Finance income 1,535 752 2,187 6,188 699 167 238 34 4,659 7,141 Finance costs (1,414) (1,178) (728) (1,113) (14) (16) (2) (1) (2,158) (2,308) Foreign exchange gain/(loss) (161) 2,509 (3,209) 2,818 - 2 - - (3,370) 5,329 Reversal of impairment losses/(impairment losses) (2,813) (2,462) (292) 6,354 66 (41) 2 3 (3,037) 3,854 Income tax (8,167) (12,612) (167) (1,027) (766) (1,017) 21 (9) (9,079) (14,665) Profit/(loss) for the year 35,808 48,624 11,830 (16,058) 2,848 3,903 10 13 50,496 36,482 Other comprehensive loss 18 (38) - - - - 2 (4) 20 (42) Total comprehensive income/(loss) 35,826 48,586 11,830 (16,058) 2,848 3,903 12 9 50,516 36,440 Unrealised profit 5,115 (3,058) - - - - - - 5,115 (3,058) Share in accumulated unrecognised losses - - (1,556) 1,556 - - - - (1,556) 1,556 Share of results of joint ventures 23,386 21,721 4,478 (6,634) 1,395 1,912 (31) 8 29,228 17,007 Dividends received 19,838 13,277 - - 691 226 - - 20,529 13,503